Mediclinic International plc Director/PDMR Shareholding (4065F)

TIDMMDC

RNS Number : 4065F

Mediclinic International plc

12 July 2019

Mediclinic International plc

(Incorporated in England and Wales)

Company Number: 08338604

LSE Share Code: MDC

JSE Share Code: MEI

NSX Share Code: MEP

ISIN: GB00B8HX8Z88

LEI: 2138002S5BSBIZTD5I60

("Mediclinic", the "Company" or the "Group")

12 July 2019

NOTIFICATION OF TRANSACTIONS BY PERSONS DISCHARGING MANAGERIAL RESPONSIBILITIES AND PERSONS CLOSELY ASSOCIATED WITH THEM

On 11 July 2019, Dr Ronnie Van der Merwe purchased 11 000 shares in Mediclinic International plc at ZAR 56.90 per share. Accordingly, Dr Van der Merwe now owns a total of 51 630 Shares.

The following notification is made in accordance with Articles 19.1 and 19.3 of the Market Abuse Regulation.

 
 1.   Details of PDMR / persons closely associated with them 
       ("PCA") 
 a)   Name                     Dr Carel Aron van der Merwe 
     -----------------------  --------------------------------------------------- 
 2.   Reason for the notification 
     ---------------------------------------------------------------------------- 
 a)   Position / status        Chief Executive Officer - Mediclinic International 
                                plc 
     -----------------------  --------------------------------------------------- 
 b)   Initial notification     Initial Notification 
       / amendment 
     -----------------------  --------------------------------------------------- 
 3.   Details of the issuer, emission allowance market participant, 
       auction platform, auctioneer or auction monitor 
     ---------------------------------------------------------------------------- 
 a)   Name                     Mediclinic International plc 
     -----------------------  --------------------------------------------------- 
 b)   LEI                      2138002S5BSBIZTD5I60 
     -----------------------  --------------------------------------------------- 
 4.   Details of the transaction(s): section to be repeated 
       for (i) each type of instrument; (ii) each type of transaction; 
       (iii) each date; and (iv) each place where transactions 
       have been conducted 
     ---------------------------------------------------------------------------- 
 a)   Description              Ordinary Shares 
       of the financial 
       instrument               GB00B8HX8Z88 
       Identification 
       Code 
     -----------------------  --------------------------------------------------- 
 b)   Nature of the            Purchase of shares 
       transaction 
     -----------------------  --------------------------------------------------- 
 c)   Price(s) and              Price(s)               Volume(s) 
       volume(s)                 ZAR 56.84 per share    1 000 
                                                       ---------- 
                                 ZAR 56.85 per share    2 831 
                                                       ---------- 
                                 ZAR 56.86 per share    1 000 
                                                       ---------- 
                                 ZAR 56.87 per share    3 000 
                                                       ---------- 
                                 ZAR 56.98 per share    2 000 
                                                       ---------- 
                                 ZAR 57.00 per share    1 169 
                                                       ---------- 
     -----------------------  --------------------------------------------------- 
 d)   Aggregated information 
       Aggregated volume 
       Price 
                                 11 000 
 
                                 ZAR 56.90 
     -----------------------  --------------------------------------------------- 
 e)   Date of the              11 July 2019 
       transaction 
     -----------------------  --------------------------------------------------- 
 f)   Place of the             Johannesburg Stock Exchange 
       transaction 
     -----------------------  --------------------------------------------------- 
 

About Mediclinic International plc

Mediclinic is an international private healthcare services group, established in South Africa in 1983, with divisions in Switzerland, Southern Africa (South Africa and Namibia) and the United Arab Emirates.

The Group's core purpose is to enhance the quality of life.

Mediclinic is focused on providing specialist-orientated, multi-disciplinary services across the continuum of care in such a way that the Group will be regarded as the most respected and trusted provider of healthcare services by patients, medical practitioners, funders and regulators of healthcare in each of its markets.

Mediclinic comprises 77 hospitals, five sub-acute hospitals, 12 day case clinics and 21 outpatient clinics. Hirslanden operates 18 hospitals, two day case clinics and three outpatient clinics in Switzerland with more than 1 900 inpatient beds; Mediclinic Southern Africa operates 52 hospitals, five sub-acute hospitals and 12 day case clinics with more than 8 500 inpatient beds; and Mediclinic Middle East operates seven hospitals, two day case clinics and 21 outpatient clinics with more than 900 inpatient beds in the United Arab Emirates.

The Company's primary listing is on the London Stock Exchange ("LSE") in the United Kingdom, with secondary listings on the JSE Ltd in South Africa and the Namibian Stock Exchange in Namibia.

Mediclinic also holds a 29.9% interest in Spire Healthcare Group plc, a leading private healthcare group based in the United Kingdom and listed on the LSE.

For further information, please contact:

Company Secretary, Link Company Matters Limited

Jayne Meacham / Caroline Emmet

[phone]

Investor Relations, Mediclinic International plc

James Arnold, Head of Investor Relations

[e-mail]

[phone]

Media queries

FTI Consulting

Brett Pollard/Debbie Scott - UK

[phone]

Sherryn Schooling - South Africa

[phone]

Registered address: 6(th) Floor, 65 Gresham Street, London, EC2V 7NQ, United Kingdom

Website: www.mediclinic.com

Joint corporate brokers: Morgan Stanley & Co International plc and UBS Investment Bank

JSE Ltd sponsor: Rand Merchant Bank (A division of FirstRand Bank Ltd)

NSX sponsor: Simonis Storm Securities (Pty) Ltd

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [e-mail] or visit www.rns.com.

END

DSHBBGDRBGBBGCD

(END) Dow Jones Newswires

July 12, 2019 07:30 ET (11:30 GMT)